JP2025508127A5 - - Google Patents
Info
- Publication number
- JP2025508127A5 JP2025508127A5 JP2024553781A JP2024553781A JP2025508127A5 JP 2025508127 A5 JP2025508127 A5 JP 2025508127A5 JP 2024553781 A JP2024553781 A JP 2024553781A JP 2024553781 A JP2024553781 A JP 2024553781A JP 2025508127 A5 JP2025508127 A5 JP 2025508127A5
- Authority
- JP
- Japan
- Prior art keywords
- drug delivery
- insert
- ophthalmic drug
- delivery insert
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263318822P | 2022-03-11 | 2022-03-11 | |
| US63/318,822 | 2022-03-11 | ||
| US202263390036P | 2022-07-18 | 2022-07-18 | |
| US63/390,036 | 2022-07-18 | ||
| PCT/US2023/064139 WO2023173088A1 (en) | 2022-03-11 | 2023-03-10 | Method of preventing age-related macular degeneration by administering an ocular drug delivery insert |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508127A JP2025508127A (ja) | 2025-03-21 |
| JP2025508127A5 true JP2025508127A5 (enExample) | 2026-04-07 |
Family
ID=85873993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553781A Pending JP2025508127A (ja) | 2022-03-11 | 2023-03-10 | 眼薬物送達インサートを投与することによる加齢黄斑変性症の予防方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250205152A1 (enExample) |
| EP (1) | EP4489749A1 (enExample) |
| JP (1) | JP2025508127A (enExample) |
| KR (1) | KR20250002220A (enExample) |
| AU (1) | AU2023230975A1 (enExample) |
| CA (1) | CA3245205A1 (enExample) |
| IL (1) | IL315331A (enExample) |
| TW (1) | TW202345803A (enExample) |
| WO (1) | WO2023173088A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008033562A2 (en) | 2006-09-15 | 2008-03-20 | Xcovery, Inc. | Kinase inhibitor compounds |
| SG11201901962QA (en) | 2016-09-29 | 2019-04-29 | Equinox Sciences Llc | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
| CA3066437A1 (en) * | 2017-06-13 | 2018-12-20 | EyePoint Pharmaceuticals, Inc. | Bioerodible drug delivery devices |
| SI4210682T1 (sl) * | 2020-09-14 | 2026-07-31 | EyePoint, Inc. | Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda |
-
2023
- 2023-03-10 IL IL315331A patent/IL315331A/en unknown
- 2023-03-10 WO PCT/US2023/064139 patent/WO2023173088A1/en not_active Ceased
- 2023-03-10 US US18/843,566 patent/US20250205152A1/en active Pending
- 2023-03-10 JP JP2024553781A patent/JP2025508127A/ja active Pending
- 2023-03-10 EP EP23715381.2A patent/EP4489749A1/en active Pending
- 2023-03-10 TW TW112108996A patent/TW202345803A/zh unknown
- 2023-03-10 KR KR1020247033914A patent/KR20250002220A/ko active Pending
- 2023-03-10 CA CA3245205A patent/CA3245205A1/en active Pending
- 2023-03-10 AU AU2023230975A patent/AU2023230975A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Casson | Medical therapy for glaucoma: A review | |
| Wang et al. | Topical medication therapy for glaucoma and ocular hypertension | |
| CN105792812B (zh) | 眼部装置 | |
| Miller et al. | Medical anti‐glaucoma therapy: Beyond the drop | |
| JP2024037864A5 (enExample) | ||
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| JP2023541056A5 (enExample) | ||
| AU2017206114A1 (en) | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| JP2025507154A5 (enExample) | ||
| JP2020505365A (ja) | 治療用および神経保護用ペプチド | |
| JP2016121163A (ja) | 眼内でのコルチコステロイド使用に伴う眼圧の発生を減少させる方法 | |
| TW202345803A (zh) | 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法 | |
| Marzok et al. | Effect of intravenous administration of romifidine on intraocular pressure in clinically normal horses | |
| JP2022524325A5 (enExample) | ||
| JP2022547231A5 (enExample) | ||
| JP2019534269A5 (enExample) | ||
| CN102210683B (zh) | 四氢嘧啶及衍生物在制备预防和治疗青光眼药物中的应用 | |
| US11207341B2 (en) | TGF-beta oligonucleotide for use in treatment of ophthalmic diseases | |
| CN120227379A (zh) | 芦可替尼在治疗年龄相关性黄斑变性中的应用 | |
| Hanhart et al. | Central serous chorioretinopathy following the BNT162b2 mRNA vaccine | |
| CN106109474B (zh) | 原人参三醇ppt在制备防治血管新生疾病药物中的用途 | |
| JP2020530459A5 (enExample) | ||
| CN106236765B (zh) | 人参皂苷Rk3在制备防治血管新生疾病的药物中的用途 | |
| Sun et al. | Single subconjunctival injection formulation using sol-gel mesoporous silica as a controlled release system for drop-free post-cataract surgery care |